DOCMF (Dr. Martens) Cash Flow from Financing: $-145 Mil (TTM As of Mar. 2026)


DOCMF Dr. Martens PLC DOCMF
53 GF Score
Price $0.97
GF Value $0.97
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Dr. Martens Cash Flow from Financing?

Dr. Martens DOCMF 53 Cash Flow from Financing is $-145 Mil as of Mar. 2026. GuruFocus rates DOCMF with a GF Score™ of 53/100 and a GF Value™ of $0.97 (Fairly Valued). The stock has 3 warning signs investors should review.

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Mar. 2026, Dr. Martens paid $0 Mil more to buy back shares than it received from issuing new shares. It received $0 Mil from issuing more debt. It paid $0 Mil more to buy back preferred shares than it received from issuing preferred shares. It spent $22 Mil paying cash dividends to shareholders. It spent $26 Mil on other financial activities. In all, Dr. Martens spent $48 Mil on financial activities for the six months ended in Mar. 2026.


Dr. Martens  (OTCPK:DOCMF) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Dr. Martens's issuance of stock for the six months ended in Mar. 2026 was $0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Dr. Martens's repurchase of stock for the six months ended in Mar. 2026 was $0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Dr. Martens's net issuance of debt for the six months ended in Mar. 2026 was $0 Mil. Dr. Martens received $0 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Dr. Martens's net issuance of preferred for the six months ended in Mar. 2026 was $0 Mil. Dr. Martens paid $0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Dr. Martens's cash flow for dividends for the six months ended in Mar. 2026 was $-22 Mil. Dr. Martens spent $22 Mil paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Dr. Martens's other financing for the six months ended in Mar. 2026 was $-26 Mil. Dr. Martens spent $26 Mil on other financial activities.


Dr. Martens Cash Flow from Financing Related Terms


Dr. Martens Cash Flow from Financing Historical Data

* Premium members only.

The historical data trend for Dr. Martens's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dr. Martens Cash Flow from Financing Chart

Dr. Martens Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only -61.92 -115.17 -236.21 -173.39 -143.73

Dr. Martens Semi-Annual Data
Mar18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -143.96 -52.38 -122.22 -63.65 -80.93
DOCMF
53GF Score
Dr. Martens PLC DOCMF
Cash Flow from Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dr. Martens Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Dr. Martens's Cash from Financing for the fiscal year that ended in Mar. 2026 is calculated as:

Dr. Martens's Cash from Financing for the quarter that ended in Mar. 2026 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-145 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow from Financing of $-145 Mil mean?
Dr. Martens (DOCMF) has a Cash Flow from Financing of $-145 Mil as of Mar. 2026. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Dr. Martens and its competitors.
Is Dr. Martens' Cash Flow from Financing too high?
Dr. Martens' current Cash Flow from Financing is $-145 Mil. Overall, Dr. Martens has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Dr. Martens' Cash Flow from Financing compare to NKE and DECK?
Dr. Martens' Cash Flow from Financing of $-145 Mil can be compared against companies in the Manufacturing - Apparel & Accessories industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Manufacturing - Apparel & Accessories company?
A good Cash Flow from Financing depends on the Manufacturing - Apparel & Accessories industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Dr. Martens and its competitors. Dr. Martens's current Cash Flow from Financing is $-145 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dr. Martens stock overvalued right now?
Based on GuruFocus' analysis, Dr. Martens (DOCMF) is currently considered Fairly Valued. The stock's GF Value™ is $0.97, compared to a current price of $0.97 — trading right at its estimated fair value. The current Cash Flow from Financing is $-145 Mil. Dr. Martens' overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Dr. Martens (DOCMF), the current Cash Flow from Financing is $-145 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dr. Martens (DOCMF) Overvalued in 2026?

Based on GuruFocus' analysis, Dr. Martens stock appears to be undervalued. The current stock price of $0.97 is trading 0% below its estimated GF Value™ of $0.97. GuruFocus considers Dr. Martens to be Fairly Valued.

Key valuation signals for DOCMF:

  • Cash Flow from Financing: $-145 Mil
  • GF Value™: $0.97 vs. price of $0.97 (0% below fair value)
  • GF Score™: 53/100 with 3 warning signs

No single metric tells the full story. See the DOCMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Dr. Martens Business Description

Address 28 Jamestown Road, Camden, London, GBR, NW1 7BY
Dr. Martens PLC is engaged in the footwear business. Its product segments include Originals, Fusion, Kids and Casual, and a complementary range of Accessories. The company has sales through E-commerce, Retail, and Wholesale of Products. Geographically, it derives the majority of its revenue from EMEA and has a presence in the Americas and APAC.
53GF Score

Get the complete analysis for DOCMF

Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.97
Price
$0.97
GF Value